MedTech Dive October 25, 2024
Hurt by a slowdown in procedures for its heart valve replacement devices, Edwards said it is working with hospitals to manage workflow challenges.
Hospital heart team capacity constraints continued to limit Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) sales in the third quarter of 2024, company executives said Thursday on an earnings call.
Global sales of the aortic valves, which are Edwards’ biggest product, increased 6.5% in the quarter from the same period a year ago to $1.02 billion.
Edwards first disclosed the workflow logjam in July, noting the dilemma affecting its TAVR procedure volumes had come as a surprise. The weak second-quarter growth sparked a selloff in the company’s shares. On Thursday, executives provided further detail on the capacity...
Today's Sponsors
Today's Sponsor